Primary Care Doctors Voice Concerns About Telehealth Companies' Role in Obesity Drug Prescribing

Primary care physicians have raised concerns about telehealth companies' involvement in prescribing obesity drugs, citing potential conflicts of interest as insurers require patients to use specific online platforms before approving expensive medications.

The issue centers on GLP-1 drugs, a class of medications that suppress appetite and have become widely prescribed for weight loss. Insurance companies have begun requiring patients seeking these drugs to first obtain approval through contracted telehealth providers rather than their personal doctors.

David Davis, a power plant worker in Aptos, California, encountered this arrangement when his insurance company required him to use Vida Health, an online telehealth company, to approve a GLP-1 prescription for obstructive sleep apnea treatment.

Telehealth companies typically offer lifestyle coaching and dietary support alongside medication prescriptions, helping patients maximize weight loss results. However, physicians worry about a secondary dynamic: employers and insurers simultaneously contract these same companies to manage spending on the high-cost drugs.

This arrangement creates a potential tension, doctors argue. While telehealth providers have financial incentives to ensure patients succeed with medications, they also face pressure from payers to limit drug spending. Physicians contend this dual role could create situations where business considerations influence medical decisions.

"There's a conflict when you're being paid to both deliver care and control costs," according to concerns raised by primary care doctors. "The patient needs to know whose interests are being prioritized."

Telehealth companies defend their model, stating they employ licensed physicians who make independent prescribing decisions based on patient medical need. Vida Health and similar platforms note they provide comprehensive support that often improves outcomes compared to patients obtaining prescriptions without structured follow-up.

The tension reflects broader questions about how the healthcare system should balance access to expensive medications with cost management. GLP-1 drugs can cost several hundred dollars monthly without insurance coverage, making cost control a legitimate concern for payers managing benefits for hundreds of thousands of employees.

Some employers have begun implementing medication management programs specifically designed to reduce spending on obesity drugs while maintaining access for appropriate patients. These programs typically include prior authorization requirements, dose limitations, or requirements that patients attempt lifestyle modifications before receiving prescriptions.

Primary care doctors say they support cost management but question whether telehealth companies with financial incentives to limit spending should serve as gatekeepers for prescriptions that their primary care physicians have already deemed medically necessary.

Insurers counter that without such controls, costs for obesity medications could consume an unsustainable share of health plan budgets. A single patient on GLP-1 therapy can cost insurers $10,000 to $15,000 annually, and millions of Americans meet clinical criteria for treatment.

The debate reflects tensions inherent in how American healthcare balances three competing priorities: ensuring patient access to effective medications, controlling costs, and preventing conflicts of interest in medical decision-making. As obesity drug use accelerates, how insurers, telehealth companies, and primary care physicians navigate these competing interests will shape prescribing practices across the country.